Posted Jun. 3, 2013 at 6:45 a.m.

Premium Lock GSK kidney cancer drug shows promise against ovarian cancer

Published: 2013-06-03 06:45:41
Updated: 2013-06-03 06:45:41

Cancer research Cancer research

Disease progression was delayed for a median of 17.9 months among patients taking Votrient, compared with 12.3 months among those on placebo, according to the study of 940 patients with advanced ovarian, fallopian tube and primary peritoneal cancer, GSK says....

Read More
Read More

WRAL TechWire any time: Twitter, Facebook

Copyright 2014 WRAL TechWire. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Best of TechWire Insider

Techwire Inside Partners

OUR INSIDERS

Dr. Mike Walden
Tech economy
Frank Vinluan
Life science
Vivek Wadhwa
Commentary
Scroll